Pharmacological therapy for people with Alzheimer's disease: The balance of clinical effectiveness, ethical issues and social and healthcare costs

Journal of Alzheimer's Disease

Volumn 12, Issue 1, 2007, Pages 53-59

  Ballard, Clive ^a,b   Sorensen, Susanne ^a   Sharp, Samantha ^a  

^a ALZHEIMER'S SOCIETY   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Cost effectiveness; National Institute for Clinical Excellence (UK)

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; MUSCARINIC AGENT; NEUROLEPTIC AGENT; NOOTROPIC AGENT; PLACEBO; RIVASTIGMINE; TALSACLIDINE;

ALZHEIMER DISEASE; BEHAVIOR DISORDER; CAREGIVER BURDEN; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; EVIDENCE BASED PRACTICE; HEALTH CARE COST; HEALTH SERVICE; HUMAN; LONG TERM CARE; MEDICAL ETHICS; META ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SOCIAL ASPECT; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 34548563836     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2007-12106     Document Type: Conference Paper

References (33)

1. National Institute for Health and Clinical Excellence, 2006, Donepezil, galantamine, rivastigmine (review) and memantine for treatment of Alzheimer's disease (final appraisal document). http://www.nice.org.uk/page. aspx?o=322952.
2. J. Birks, J. Grimley Evans, V. Iakovidou and M. Tsolaki, Rivastigmine for Alzheimer's disease, Cochrane Dementia and Cognitive Improvement Group Cochrane Database of Systematic Reviews 4 (2006).
3. C. Loy and L. Schneider, Galantamine for Alzheimer's disease and mild cognitive impairment, Cochrane Dementia and Cognitive Improvement Group Cochrane Database of Systematic Reviews 4 (2006).
4. J. Birks and R.J. Harvey, Donepezil for dementia due to Alzheimer's disease, Cochrane Dementia and Cognitive Improvement Group Cochrane Database of Systematic Reviews 4 (2006).
5. National Institute for Health and Clinical Excellence, 2005, Additional analyses and addenda (Technical report no.2 and MRC Report), http://www.nice.org.uk/page.aspx?o=288375.
6. G. Livingston and C. Katona, How useful are cholinesterase inhibitors in the treatment of Alzheimer's disease: a number needed to treat analysis, Int J Geriatric Psych 15 (2000), 203-207.
7. H. Feldman, S. Gauthier, J. Hecker, B. Vellas, M. Hux, Y. Xu, E.M. Schwam, S. Shah and V. Mastey, Donepezil MSAD Study Investigators Group. Economic evaluation of donepezil in moderate to severe Alzheimer disease, Neurol 63 (2004), 644-650.
8. L. Jonsson, P. Lindgren, A. Wimo, B. Jonsson and B. Winblad, The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: A Markov model, Clin Ther 21 (1999), 1230-1240.
9. B.J. O'Brien, R. Goeree, M. Hux, M. Iskedjian, G. Blackhouse, M. Gagnon and S. Gauthier, Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada, J Am Geriatr Soc 47 (1999), 570-578.
10. A. Gafni and S. Birch, Preferences for outcomes in economic evaluation: an economic approach to addressing economic problems, Social Sci & Med 40 (1995), 767-776.
11. National Institute for Clinical Excellence, 2001, Donepezil, Rivastigmine and Galantamine for the Treatment of Alzheimer's Disease. http://www.nice.org.uk/guidance/TA19.
12. National Institute for Health and Clinical Excellence, 2004, Donepezil, galantamine, rivastigmine (review) and memantine for treatment of Alzheimer's disease (assessment report). http://www.nice.org.uk/page.aspx?o= 245910.
13. J.J. Caro, D. Getsios, K. Migliaccio-Walle, G. Raggio and A. Ward, Assessment of health economics in Alzheimer's disease (AHEAD) based on need for full-time care, Neurol 57 (2001), 964-971.
14. Department of Health, 2005, Response to Appraisal Consultation Document, Leeds, Department of Health, http://www.nice.org.uk/page.aspx?o= 288562.
15. National Institute for Health and Clinical Excellence, 2005, Donepezil, galantamine, rivastigmine (review) and memantine for treatment of Alzheimer's disease (appraisal consultation document-2). http://www.nice.org.uk/ page.aspx?o=288826.
16. P.J. Neumann, K.M. Kuntz, J. Leon, S.S. Araki, R.C. Hermann, M.A. Hsu and M.C. Weinstein, Health utilities in Alzheimer's disease: a cross-sectional study of patients and caregivers, Med Care 37 (1999), 27-32.
17. M. Sano, G.K. Wilcock, B. van Baelen and S. Kavanagh, The effects of galantamine treatment on caregiver time in Alzheimer's disease, Int J Geriatric Psych 18 (2003), 942-950.
18. A. Wimo, B. Winbald, A. Stoffler, Y. Wirth and H.J. Mobius, Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease, Pharmacoeconomics 21 (2003), 327-340.
19. N.L. Mace and P.V. Rabins, The 36-Hour Day: AFamily Guide to Caring for Persons With Alzheimer Disease, Related Dementing Illnesses, and Memory Loss in Later Life, Baltimore: Johns Hopkins University Press, Baltimore, 1981.
20. O. Zanetti, G.B. Frisoni, A. Bianchetti, G. Tamanza, V. Cigoli and M. Trabucchi, Depressive symptoms of Alzheimer caregivers are mainly due to personal rather than patient factors, Int J Geriatric Psych 13 (1998), 358-367.
21. J.L. Cummings, B. Koumaras, M. Chen and D. Mirski, Rivastigmine Nursing Home Study Team. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study, Am J Geriatric Pharmacotherapy 3 (2005), 137-148.
22. P.N. Tariot, M.R. Farlow, G.T. Grossberg, S.M. Graham, S. McDonald and I. Gergel, Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil, JAMA 291 (2004), 317-324.
23. K. Rockwood, S. Fay, X. Song, C. MacKnight and M. Gorman, Video-Imaging Synthesis of Treating Alzheimer's Disease (VISTA) Investigators. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial, CMAJ 174 (2006), 1099-1105.
24. C. Courtney, D. Farrell, R. Gray, R. Hills, L. Lynch, E. Sellwood, S. Edwards, W. Hardyman, J. Raftery, P. Crome, C. Lendon, H. Shaw and P. Bentham, AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial, Lancet 363 (2004), 105-115.
25. M.A. Raskind, E.R. Peskind, L. Truyen, P. Kershaw and C.V. Damaraju, The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial, Archives of Neurol 61 (2004), 252-256.
26. Z. Gu, P. Zhong and Z. Yan, Activation of muscarinic receptors inhibits beta-amyloid peptide-induced signaling in cortical slices, J Biol Chem 278 (2003), 17546-17556.
27. N.P. Verhoeff, Acetylcholinergic neurotransmission and the beta-amyloid cascade: implications for Alzheimer's disease, Expert Rev Neurother 5 (2005), 277-284.
28. C. Hock, A. Maddalena, A. Raschig, F. Muller-Spahn, G. Eschweiler, K. Hager, I. Heuser, H. Hampel, T. Muller-Thomsen, W. Oertel, M.Wienrich, A. Signorell, C. Gonzalez-Agosti and R.M. Nitsch, Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease, Amyloid 10 (2003), 1-6.
29. T. Darreh-Shori, O. Almkvist, Z.Z. Guan, A. Garlind, B. Strandberg, A.L. Svensson, H. Soreq, E. Hellstrom-Lindahl and A. Nordberg, Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months, Neurol 59 (2002), 563-572.
30. E.K. Perry, L. Kilford, A.J. Lees, D.J. Burn and R.H. Perry, Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs, Annals of Neurol 54 (2003), 235-238.
31. C.G. Ballard, K. Chalmers, C. Todd, I.G. McKeith, J.T. O'Brien, G. Wilcock, S. Love and E.K Perry, Cholinesterase Inhibitors Reduce Cortical Aβ in Dementia with Lewy bodies, Neurol 68 (2007), 1726-1729.
32. M. Hashimoto, H. Kazui, K. Matsumoto, Y. Nakano, M. Yasuda and E Mori, Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? Am J Psych 162 (2005), 676-682.
33. J.T. O'Brien, NICE and anti-dementia drugs: a triumph of health economics over clinical wisdom? Lancet Neurol 5 (2006), 994-996.